# Syringe Needle Market

> Syringe and Needle Market Research Report By Type (Blood Collection Syringes and Needles, Ophthalmic Syringes and Needles, Bone Marrow Syringes and Needles, Catheter Syringes and Needles), By Application (General Surgery, Diagnostic, Respiratory, Orthopedics, Cardiovascular, Dental), By Usability (Disposable, Reusable) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Industry Forecast to 2035.

- **Forecast Period:** 2026-2035
- **CAGR:** 6.95%
- **2025:** USD 28.10 Billion (2025)
- **2026:** USD 30.05 Billion
- **2035:** USD 55.01 Billion
- **Key Players:** Terumo Corporation, B. Braun Melsungen AG, Nipro Corporation, Cardinal Health, Gerresheimer AG, Smiths Medical (ICU Medical), Retractable Technologies Inc., Hindustan Syringes & Medical Devices

**Report ID:** MRFR/MED/0252-HCR · **Pages:** 105 · **Author:** Rahul Gotadki & Kinjoll Dey · **Last Updated:** July 20, 2026

**URL:** https://www.marketresearchfuture.com/reports/syringe-needle-market-723

---

## Market Summary

The Global Syringe and Needle Market size was valued at USD 9.85 Billion in 2024, and the market is projected to grow from USD 10.36 Billion in 2025 to USD 17.14 Billion by 2035, registering a CAGR of 5.16% during the forecast period 2025–2035. North America led the market in 2024 with over 39.59% share, generating around USD 3.9 Billion in revenue.
 
The Syringe and Needle Market is primarily driven by the rising global demand for injectable therapies, vaccination programs, and routine diagnostic procedures. Increasing chronic disease prevalence and expanding healthcare access are accelerating the adoption of safe, disposable, and technologically advanced syringes and needles across hospitals and clinics worldwide.
 
According to WHO data, global immunization programs deliver more than 16 billion injections annually, with over 90% administered for curative and preventive healthcare purposes, significantly supporting long-term syringe and needle demand growth.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Rising global diabetes prevalence | ~22% | Global | Long-term (≥4 yr) | [6] |
| Expanded immunization and booster programs | ~18% | Asia-Pacific, Africa | Medium-term (2–4 yr) | [1] |
| GLP-1 and biologics injection volume growth | ~17% | North America, Europe | Short-term (≤2 yr) | [7] |
| Needlestick safety regulations | ~15% | North America, EU | Medium-term (2–4 yr) | [2] |
| Home-healthcare and self-administration shift | ~14% | Global | Long-term (≥4 yr) | [8] |
| Point-of-care diagnostics expansion | ~8% | Asia-Pacific, Latin America | Medium-term (2–4 yr) |   |
| Smart and connected injection devices | ~6% | North America, Europe | Long-term (≥4 yr) |   |

### Rising Global Diabetes Prevalence

In 2021, the International Diabetes Federation reported that 537 million adults aged 20–79 were living with diabetes. This figure is anticipated to increase to 783 million by 2045 [[6]](https://diabetesatlas.org). Annually, over 1 billion syringe and needle units are consumed for diabetes management alone, as insulin-dependent patients require an average of 3–4 daily injections or regular pen-needle changes. In the Syringe and Needle Market, procurement volumes are being driven by national programs such as India's PM Abhiyan and the U.S. Medicare Part D insulin limit at USD 35 per month, which are expanding access.

### Expanded Immunization and Booster Programs

WHO and UNICEF shipped approximately 3.4 billion vaccine doses in 2023, each requiring at least one syringe-needle assembly [[1]](https://who.int). The introduction of year-round adult booster schedules for influenza, COVID-19, and RSV — combined with Gavi's allocation of USD 11.9 billion for 2026–2030 immunization commitments — sustains high-volume recurring demand across the Syringe and Needle Market, particularly in Sub-Saharan Africa and Southeast Asia.

### GLP-1 and Biologics Injection Volume Growth

The rapid clinical adoption of semaglutide and tirzepatide has created a step-change in subcutaneous injection volumes. Global GLP-1 receptor agonist sales exceeded USD 50 billion in 2024, with each weekly dose requiring a single-use pen needle or syringe [[7]](https://iqvia.com). This has placed pressure on supply chains and is redirecting manufacturer capacity toward pre-fillable glass and polymer syringe barrels optimized for viscous biologic formulations.

### Needlestick Safety Regulations

OSHA's Bloodborne Pathogens Standard and the EU Directive 2010/32/EU mandate the use of sharps-injury prevention devices across healthcare settings. Non-compliance penalties can reach USD 156,259 per willful violation in the U.S. [[2]](https://osha.gov). These regulations have shifted hospital purchasing budgets toward retractable, shielded, and blunting needle systems, creating a sustained premium-product migration within the Syringe and Needle Market.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Price erosion from generic/low-cost imports | ~−1.8% | Global | Short-term (≤2 yr) | [11] |
| Needle-free injection technology substitution | ~−1.4% | North America, Europe | Long-term (≥4 yr) |   |
| Regulatory fragmentation across emerging markets | ~−1.1% | Asia-Pacific, Africa | Medium-term (2–4 yr) | [13] |
| Sharps waste disposal and environmental concerns | ~−0.9% | Europe, North America | Medium-term (2–4 yr) | [14] |
| Raw material supply chain disruptions | ~−0.7% | Global | Short-term (≤2 yr) |   |

### Price Erosion from Generic and Low-Cost Imports

Commoditization of standard [disposable syringes](https://www.marketresearchfuture.com/reports/disposable-syringes-market-43208) has driven average selling prices down by 12–15% between 2020 and 2024 in several Asian and African markets [[11]](https://worldbank.org). Chinese and Indian contract manufacturers now supply over 60% of global disposable syringe volume, compressing margins for branded players and reducing overall Syringe and Needle Market revenue growth despite unit volume expansion.

### Needle-Free Injection Technology Substitution

Jet injectors, microneedle patches, and oral biologics delivery platforms represent a long-term competitive threat. The needle-free injection market is projected to exceed USD 18 billion by 2032. While current adoption remains limited to niche vaccine delivery and specific dermatological applications, continued investment by pharma companies could erode the addressable portion of the Syringe and Needle Market over the forecast period.

### Sharps Waste and Environmental Concerns

Globally, an estimated 16 billion injections are administered annually, resulting in substantial quantities of sharps residue [[14]](https://practicegreenhealth.org). Procurement teams are being compelled to assess reusable or biodegradable alternatives in the Syringe and Needle Market due to growing hospital sustainability mandates and tightening EU regulations on single-use plastics. This has resulted in cost headwinds for conventional single-use devices.

## Opportunities

## Syringe Needle Market Opportunities

### Connected and Smart Injection Devices

Bluetooth-enabled auto-injectors and connected pen needles that transmit dose-timing data to companion apps represent a high-growth adjacency. Pharmaceutical companies are embedding NFC chips into syringe packaging for track-and-trace compliance under the EU Falsified Medicines Directive, creating a hardware upgrade cycle worth an estimated USD 2.1 billion by 2030.

### Emerging Market Immunization Infrastructure

There is still a lack of penetration for routine immunization in Sub-Saharan Africa and South Asia. The investment strategy of GAVI for the years 2026–2030 is designed to target an additional 300 million children in 57 countries, each of whom necessitates multiple injection contacts [[1]](https://who.int). In the Syringe and Needle Market, manufacturers who establish local fill-finish partnerships or transmit auto-disable syringe technology have the potential to capture significant recurring volume.

### Self-Administration and Home-Healthcare Platforms

The shift toward patient self-injection for biologics, insulin, and fertility treatments is expanding the Syringe and Needle Market beyond traditional institutional channels. Over 40% of new biologic drug approvals between 2022 and 2025 included a subcutaneous self-administration pathway, and home-healthcare spending in the U.S. is forecast to exceed USD 200 billion by 2028 [[8]](https://cms.gov).

### Specialty Needle Applications in Diagnostics

Liquid biopsy, microsampling, and capillary blood collection techniques are driving demand for ultra-fine-gauge specialty needles. The global point-of-care diagnostics market is expanding at over 9% annually, and each testing platform requires compatible needle-syringe assemblies for sample acquisition.

### Sustainable and Recyclable Device Design

Hospital procurement organizations in Scandinavia and the UK have begun weighting sustainability criteria at 10–15% in tender evaluations [[14]](https://practicegreenhealth.org). Companies developing bio-based polymer syringes or closed-loop needle recycling systems can differentiate in the Syringe and Needle Market and capture premium pricing tiers.

## Future Outlook

## Syringe Needle Market Future Outlook

### AI-Optimized Manufacturing and Quality Control

Machine-vision inspection systems are replacing manual quality checks on syringe production lines, with defect detection accuracy exceeding 99.7%. By 2030, manufacturers adopting AI-driven predictive maintenance and real-time dimensional measurement are expected to reduce production waste by 18–22%, strengthening margins across the Syringe and Needle Market while meeting tightening regulatory quality thresholds.

### Platform Economics and Drug-Device Convergence

Pharmaceutical companies are increasingly co-developing injectable drugs alongside proprietary delivery platforms, binding patients to specific syringe-needle ecosystems. This drug-device convergence mirrors the razor-razorblade model, where the delivery device generates recurring aftermarket revenue. The Syringe and Needle Market will see consolidated partnerships between CDMOs and device OEMs through the late 2020s [[21]](https://.com).

### Sustainability and Circular Device Design

In the United States alone, the healthcare sector is responsible for the generation of an estimated 5.9 million tons of waste annually, with sharps accounting for a substantial portion [[14]](https://practicegreenhealth.org). The Syringe and Needle Market is being driven toward recyclable polymer containers and reduced-plastic packaging by the European Green Deal targets and NHS Net Zero commitments. It is anticipated that procurement tenders will incorporate life-cycle assessment (LCA) requirements by 2028.

### Decentralized Clinical Trials and Self-Injection

Decentralized and hybrid clinical trial designs rose from 7% to 34% of all new trials between 2019 and 2024, and each home-based dosing event requires patient-administered injection kits [[22]](https://fda.gov). This shift expands the Syringe and Needle Market's addressable channels from institutional to direct-to-patient, demanding simplified device ergonomics, training-integrated packaging, and cold-chain-compatible syringe formats.

## Segment Insights

## Syringe Needle Market Segmentation

### By Product Category

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Syringes (Disposable and Reusable) | 70.2% share (2025) | Immunization mandates and auto-disable requirements |
| Needles (Hypodermic and Specialty) | 7.45% CAGR (2026–2035) | Blood collection and diagnostics growth |

Syringes dominate the Syringe and Needle Market by product category, with disposable formats accounting for the vast majority of unit volumes. WHO's global mandate for auto-disable syringes in immunization programs ensures sustained procurement from UNICEF Supply Division, which distributed 2.4 billion syringes in 2023 alone [[1]](https://who.int). Reusable syringes retain a niche in veterinary and laboratory settings where sterilization protocols are established.

Needles represent the faster-growing product segment, propelled by expanding applications in blood collection, biopsy sampling, and interventional radiology. Ultra-fine-gauge needles (31G–34G) are gaining traction in insulin and biologics delivery for improved patient comfort, and specialty needle designs for cryoablation and nerve-block procedures are commanding premium pricing in the Syringe and Needle Market.

### By Material

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Plastic | 48.4% share (2025) | Cost-effective disposable formats |
| Glass | USD 6.18 Billion (2025) | Prefilled syringe compatibility with biologics |
| Stainless Steel and Others | 7.35% CAGR (2026–2035) | Precision specialty needle applications |

Plastic remains the dominant material in the Syringe and Needle Market, used primarily for polypropylene syringe barrels and polyethylene plunger components. Glass syringe barrels are critical for prefilled formats where drug-container compatibility and low extractable profiles are required — Type I borosilicate glass remains the gold standard for biologic storage. Stainless steel is essential for all needle cannulae and is expanding as specialty needle applications grow.

### By Application

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Insulin Administration | 32.6% share (2025) | Global diabetes epidemic |
| Vaccination | USD 5.90 Billion (2025) | Routine and pandemic immunization |
| Blood Collection | 7.60% CAGR (2026–2035) | Point-of-care diagnostics expansion |
| Drug Administration (Other Injectables) | 18.5% share (2025) | Biologics and oncology therapies |
| Others | USD 1.95 Billion (2025) | Veterinary and research applications |

Insulin administration commands the largest application share in the Syringe and Needle Market as the diabetes patient population grows at approximately 3% annually, with each patient consuming 100–1,500 needle units per year depending on therapy regimen [[6]](https://diabetesatlas.org). Blood collection is the fastest-growing application segment, driven by laboratory automation and the expansion of blood bank infrastructure across developing nations where donation rates remain below WHO targets of 10 per 1,000 population.

### By End User

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Hospitals and Clinics | 49.1% share (2025) | High-volume institutional procurement |
| Home Healthcare | 7.65% CAGR (2026–2035) | Chronic disease self-management |
| Ambulatory Surgery Centers | USD 3.65 Billion (2025) | Outpatient procedure migration |
| Others (Labs, Blood Banks) | 10.8% share (2025) | Diagnostic and research demand |

Hospitals and clinics remain the largest end-user channel in the Syringe and Needle Market, driven by GPO-negotiated bulk procurement contracts and standardized formulary requirements. Home healthcare is the fastest-growing channel as payers incentivize outpatient management of diabetes, rheumatoid arthritis, multiple sclerosis, and other chronic conditions requiring regular injections [[8]](https://cms.gov).

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric | Primary Investment Themes |
| --- | --- | --- |
| North America | 36.4% share (2025) | Biologics delivery, needlestick safety compliance |
| Europe | USD 7.59 Billion (2025) | MDR compliance, sustainability mandates |
| Asia-Pacific | 7.75% CAGR (2026–2035) | Universal health coverage, local manufacturing |
| South America | USD 2.25 Billion (2025) | Public immunization, diabetes management |
| Middle East & Africa | 7.20% CAGR (2026–2035) | Immunization access, cold chain expansion |
| Total | USD 28.10 Billion (2025) | — |

The Syringe and Needle Market exhibits distinct regional dynamics shaped by healthcare infrastructure maturity, regulatory frameworks, and disease burden profiles.

### North America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| United States | 78.2% of regional share | Medicare Part D insulin access, OSHA mandates |
| Canada | 12.5% of regional share | Provincial procurement modernization |
| Mexico | 9.3% of regional share | INSABI universal health program |

The United States dominates the North American Syringe and Needle Market, driven by the highest per-capita injectable biologic utilization globally. FDA clearances for combination products — where the drug and delivery device are regulated as a single entity — rose 23% between 2022 and 2024, accelerating the Syringe and Needle Market upgrade cycle toward integrated prefilled formats [[16]](https://bd.com). Canada's bulk provincial purchasing agreements and Mexico's transition to the IMSS-Bienestar centralized procurement model add steady volume growth across the region.

### Europe

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Germany | 6.45% CAGR | Hospital automation and chronic disease management |
| United Kingdom | USD 1.18 Billion (2025) | NHS procurement consolidation |
| France | 16.8% of regional share | National diabetes plan investment |
| Italy | 12.4% of regional share | Aging population and insulin demand |
| Spain | 5.95% CAGR | Expanded primary care injection capacity |
| Nordic Countries | USD 0.52 Billion (2025) | Sustainability-driven procurement |
| Russia | 8.1% of regional share | Import substitution policy |
| Rest of Europe | 6.10% CAGR | EU MDR harmonization |

Europe's Syringe and Needle Market is shaped by the Medical Device Regulation (MDR 2017/745), which requires enhanced post-market surveillance and UDI traceability for all injection devices sold in the EU. Germany's Krankenhausreform hospital reform act is channeling investment into automated medication preparation systems that consume standardized syringe formats, while the UK's NHS centralized procurement through the Supply Chain Coordination Limited (SCCL) has compressed supplier margins but increased unit volumes [[17]](https://ec.europa.eu).

### Asia-Pacific

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| China | 34.5% of regional share | Centralized volume-based procurement (VBP) |
| India | 8.20% CAGR | Ayushman Bharat and local manufacturing |
| Japan | USD 1.42 Billion (2025) | Aging demographics and biologics adoption |
| South Korea | 6.85% CAGR | Biosimilar production scaling |
| ASEAN | 15.2% of regional share | Immunization coverage expansion |
| Rest of Asia-Pacific | 6.70% CAGR | Healthcare infrastructure build-out |

Asia-Pacific is the fastest-growing region in the Syringe and Needle Market, led by China's volume-based procurement program that has driven syringe prices down by 40–60% while dramatically increasing utilization volumes [[18]](https://nipro.co.jp). India's production-linked incentive (PLI) scheme allocated INR 27 billion for medical device manufacturing between 2021 and 2028, attracting BD, Nipro, and domestic players to establish auto-disable syringe capacity exceeding 5 billion units annually. Japan's aging society — 29.1% of the population is over 65 — sustains steady demand for insulin delivery and biologics injection systems.

### South America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Brazil | 58.7% of regional share | SUS public health procurement |
| Argentina | 6.40% CAGR | Diabetes prevalence growth |
| Rest of South America | USD 0.54 Billion (2025) | Pan American Health Organization programs |

Brazil's Sistema Único de Saúde (SUS) is the largest single public purchaser in the region, distributing over 800 million syringe-needle units annually across 5,570 municipalities [[19]](https://gov.br). The Syringe and Needle Market in South America benefits from PAHO's revolving fund mechanism, which pools procurement across member states to negotiate competitive pricing for immunization supplies.

### Middle East & Africa

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 28.3% of regional share | Vision 2030 healthcare expansion |
| UAE | 6.95% CAGR | Medical tourism and premium device adoption |
| South Africa | USD 0.31 Billion (2025) | HIV/TB injection therapy programs |
| Egypt | 18.5% of regional share | Population scale and public health campaigns |
| Rest of MEA | 7.40% CAGR | Gavi-supported immunization programs |

The Middle East & Africa Syringe and Needle Market is characterized by dual dynamics: Gulf states investing in premium hospital infrastructure and advanced injection systems, while Sub-Saharan Africa relies heavily on donor-funded auto-disable syringe supply chains. Saudi Arabia's National Transformation Program has earmarked USD 65 billion for healthcare infrastructure through 2030, including localized medical device manufacturing [[20]](https://vision2030.gov.sa).

## Competitive Benchmarking

## Competitive Benchmarking

The Syringe and Needle Market exhibits low-to-moderate concentration, with the top five players controlling an estimated 45–50% of global revenue. The HHI index sits below 1,000, reflecting a fragmented competitive structure where large multinationals compete alongside regional specialists and contract manufacturers. Competitive differentiation increasingly depends on safety-engineering capabilities, prefilled syringe manufacturing capacity, and integrated drug-device partnership agreements [[21]](https://.com).

| Company | Est. Revenue Share Range | Key Offerings | Strategic Positioning |
| --- | --- | --- | --- |
| Becton, Dickinson and Company (BD) | ~14–18% | Disposable syringes, safety needles, prefilled systems | Global market leader with broadest product portfolio |
| Terumo Corporation | ~8–11% | Hypodermic needles, insulin syringes, blood collection | Precision engineering and thin-wall needle technology |
| B. Braun Melsungen AG | ~6–9% | Disposable syringes, IV administration sets | European market strength with integrated infusion systems |
| Nipro Corporation | ~5–7% | Disposable syringes, pen needles, glass prefillable barrels | High-volume OEM manufacturing for pharma partners |
| Cardinal Health | ~4–6% | Syringe distribution, private-label devices | Supply chain and distribution network scale |
| Gerresheimer AG | ~3–5% | Glass and polymer prefillable syringe systems | Drug-device packaging and primary containment |
| Smiths Medical (ICU Medical) | ~3–5% | Safety syringes, needle-free connectors | Acute care and infusion therapy specialization |
| Retractable Technologies Inc. | ~2–3% | Retractable safety syringes and blood collection | Patent-protected retractable needle mechanism |
| Hindustan Syringes & Medical Devices | ~2–4% | Auto-disable syringes, disposable syringes | Largest AD syringe manufacturer by volume |
| Medline Industries | ~2–3% | Private-label syringes, procedure kits | U.S. hospital distribution and bundled supply contracts |

## Recent News & Developments

## Recent News & Developments

- Terumo Corporation (June 2024): Launched the Nanopass 34G ultra-thin needle in the European market, targeting pain-free insulin delivery for pediatric and elderly diabetic patients [[23]](https://terumo.com).
- B. Braun Melsungen (March 2024): Received CE marking under MDR 2017/745 for its Introcan Safety IV catheter system, extending its safety-device portfolio in the Syringe and Needle Market [[17]](https://ec.europa.eu).

- WHO/UNICEF (January 2024): Awarded a three-year, 4.5-billion-unit auto-disable syringe supply contract to Hindustan Syringes & Medical Devices and Star Syringe for Gavi-supported immunization programs [[1]](https://who.int).

## Report Scope

## Syringe Needle Market Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global Syringe and Needle Market |
| Study Period | 2021–2035 |
| CAGR (Forecast Period) | 6.95% (2026–2035) |
| Base Year Value | USD 28.10 Billion (2025) |
| 2026 Forecast Value | USD 30.05 Billion |
| 2035 Forecast Value | USD 55.01 Billion |
| Fastest Growing Segment | Needles by product; Home Healthcare by end user |
| Companies Profiled | 10+ (BD, Terumo, B. Braun, Nipro, Cardinal Health, Gerresheimer, Smiths Medical, Retractable Technologies, Hindustan Syringes, Medline Industries, and others) |
| Valuation Currency | USD Billion |

## Frequently Asked Questions

**Q: How do hospital group purchasing organizations influence syringe procurement pricing?**
A: GPOs aggregate purchasing volume across member hospitals to negotiate 15–30% discounts from list price. Contracts typically lock for 2–3 years, limiting mid-cycle supplier switching [16].

**Q: What quality certifications should buyers verify before sourcing injection devices?**
A: Confirm ISO 7886-1 for single-use syringes, ISO 7864 for sterile needles, and CE marking or 510(k) clearance. WHO prequalification is essential for donor-funded procurement [13].

**Q: How does needle gauge selection affect clinical outcomes in biologics delivery?**
A: Thinner gauges (29G–34G) reduce injection pain and improve patient adherence. However, high-viscosity biologics may require 25G–27G to maintain acceptable injection time under 15 seconds [23].

**Q: What are the total cost-of-ownership differences between safety and conventional syringes?**
A: Safety devices cost 20–40% more per unit but reduce needlestick injury costs, averaging USD 3,000 per incident. Facilities typically achieve net savings within 18 months of conversion [2].

**Q: How are cold-chain requirements shaping syringe material choices for biologic drugs?**
A: Cyclic olefin polymer barrels outperform glass in freeze-thaw stability for biologic storage at −20°C. Pharma companies increasingly specify COP for mRNA and antibody-based therapies [21].

**Q: What role do contract device manufacturers play in the Syringe and Needle Market?**
A: CDMOs handle 30–35% of global prefilled syringe fill-finish volume, enabling pharma companies to launch injection products without investing in dedicated device manufacturing lines [18].

**Q: How might microneedle patch technology reshape the Syringe and Needle Market by 2035?**
A: Dissolving microneedle patches are in Phase II/III trials for vaccines and insulin. Widespread adoption could displace 8–12% of conventional syringe volumes in specific applications by 2035 [12].

**Q: What is the current size of the syringe and needle market?**
A: The syringe and needle market reached USD 28.10 billion in 2025 and is projected to reach USD 55.01 billion by 2035.

**Q: What is the CAGR of the syringe and needle market?**
A: The syringe and needle market is projected to grow at a CAGR of 6.95% during the forecast period 2026–2035.

**Q: Which region leads the syringe and needle market?**
A: North America holds the largest share at 36.4%, while Asia-Pacific is the fastest-growing region at 7.75% CAGR.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/syringe-needle-market-723*